US.COR · Cencora

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.5344016637808724,
        "turnoverUsdM": 287.75125970445004,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.COR",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 305.0614,
      "strength_details": {
        "ma_score": 1,
        "atr_score": 2,
        "rsi_score": 3,
        "macd_score": 2.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.2,
      "stop_loss_percent": 5.1,
      "take_profit_price": 341.2085,
      "target_multiplier": 1.9,
      "technical_strength": 1.93,
      "take_profit_percent": 6.2
    },
    "positionPoints": 1.6,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2231683889345923,
    "stopLossPercent": 5.068803327561745,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 73,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 64,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 9
  },
  "market": {
    "ma20": 313.408,
    "ma50": 317.9072,
    "close": 321.35,
    "prevClose": 317.25,
    "avgVolume20": 1243042,
    "volumeRatio": 0.72,
    "changePercent": 1.29
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 9,
    "details": {
      "ret_5d": 0.03734911872942104,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 9,
      "vcp_bonus": 0,
      "vol_ratio": 0.7075344603483764,
      "ret_points": 8,
      "vol_points": 0,
      "range_ratio": 0.9587457990511932,
      "volat_points": 0,
      "day_range_pct": 0.023899174610263765,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 73,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 3.6,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 72,
        "contribution": 3.6
      },
      {
        "raw": 12.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 62,
        "contribution": 12.4
      },
      {
        "raw": 12.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 84,
        "contribution": 12.6
      },
      {
        "raw": 6,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 6.8,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 68,
        "contribution": 6.8
      },
      {
        "raw": 19.6,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 65.33,
        "contribution": 19.6
      },
      {
        "raw": 3,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 30,
        "contribution": 3
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 64,
    "details": [
      "基本面分析總分: 3.6/5分",
      "資金流分析總分: 12.4/20分",
      "市場環境分析總分: 12.6/15分",
      "催化劑分析: 6/20分",
      "風險管理總分: 6.8/10分",
      "技術信號分析總分: 19.6/30分",
      "情緒分析: 3/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 6,
      "基本面": 3.6,
      "資金流": 12.4,
      "市場環境": 12.6,
      "情緒分析": 3,
      "技術信號": 19.6,
      "風險管理": 6.8
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 7,
              "catalystCount": 1
            }
          },
          "catalystPoints": 6
        }
      },
      "基本面": {
        "max": 5,
        "grade": "良好",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.4,
          "epsPoints": 0,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0,
          "turnoverUsdM": 287.75125970445004,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "一般",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 1.6,
          "obvPoints": 4,
          "vwapPoints": 3.2,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.COR",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "優秀",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 15.08
            }
          },
          "trend": {
            "score": 4,
            "details": {
              "qqq": {
                "ma20": 735.7219992500001,
                "ma50": 723.1690000399999,
                "name": "QQQ",
                "close": 747.58002,
                "points": 2
              },
              "spy": {
                "ma20": 767.26299675,
                "ma50": 766.83679764,
                "name": "SPY",
                "close": 773.92999,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.5344016637808724,
          "atrPoints": 3,
          "cciPoints": 3.2,
          "vixPoints": 2.4,
          "marketTrendPoints": 4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 3,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 7,
              "negativeHits": 0,
              "positiveHits": 1,
              "sentimentScoreRaw": 0.3
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142289012,
                "url": "https://finnhub.io/api/news?id=a46dc376ff20cc5020fa2758951534772ec27b451a1e7b71bbe3cfb6e7252a2a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Cencora (COR) just combined a stronger fiscal third quarter, a higher full year adjusted EPS outlook, and a US$1b buyback with plans to brief investors at two New York healthcare conferences. Despite the upbeat earnings message, Cencora’s share price has eased in the short term, with a 7 day share price return of down 3.98% and a 30 day share price return of down 2.91% from US$308.78. At the same time, a 90 day share price return of 13.82% and a 1 year total shareholder return of 7.28% sit...",
                "category": "company",
                "datetime": 1789913304,
                "headline": "Cencora (COR) Lifts EPS Outlook And Buyback, Is The Stock Still Below Fair Value?"
              },
              {
                "id": 142271052,
                "url": "https://finnhub.io/api/news?id=43f6da2bdc370d90df2f35e5bc95ec1f7dbb6c62d461277f16c156c2d243919f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "On August 5, Cencora (NYSE:COR) reported results for its fiscal third quarter, which closed on June 30, and the headline numbers looked clean. Revenue rose 5.1% to $84.8 billion, adjusted earnings per share climbed 12.0% to $4.48, and management raised its full-year adjusted EPS outlook to $17.75 to $17.95. The company also repurchased $1 billion […]",
                "category": "company",
                "datetime": 1789821517,
                "headline": "Cencora (COR) Raised Guidance and Bought Back $1B. What’s the Catch?"
              },
              {
                "id": 142168849,
                "url": "https://finnhub.io/api/news?id=b34af31dcda5b814375c7dd7a24aeb1542306abf17d73d352a1296887c2d010c",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "COR",
                "summary": "Cencora, Inc. (COR) 2026 Global Healthcare Conference September 15, 2026 3:10 PM EDTCompany ParticipantsEva Boratto - Executive VP & CFORobert Mauch -...",
                "category": "company",
                "datetime": 1789495297,
                "headline": "Cencora, Inc. (COR) Presents at 2026 Global Healthcare Conference Transcript"
              },
              {
                "id": 142164126,
                "url": "https://finnhub.io/api/news?id=a66b11ff690d6b717fc56cc954cbd060c681b8a97b4cc86d4699d13e6d045cf8",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "COR",
                "summary": "Cencora, Inc. (COR) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 8:30 AM EDTCompany ParticipantsRobert Mauch - President, CEO...",
                "category": "company",
                "datetime": 1789470099,
                "headline": "Cencora, Inc. (COR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript"
              },
              {
                "id": 142132277,
                "url": "https://finnhub.io/api/news?id=61290999a6a25626631ed778e2196923d31c2a4fa838d94564f8ae7ff970ab8b",
                "image": "https://www.chartmill.com/images/uploads/thumbnail_article_luc_kroeze_c1f44c837d.webp",
                "source": "ChartMill",
                "related": "COR",
                "summary": "Cencora (COR) scores well on EBIT growth, cash-backed profits and debt/FCF, but thin margins and high debt/equity warrant caution for quality investors.",
                "category": "company",
                "datetime": 1789373469,
                "headline": "Cencora (NYSE:COR): A Quality Stock With Strong EBIT Growth and Cash Conversion"
              },
              {
                "id": 141955203,
                "url": "https://finnhub.io/api/news?id=8eee7a83d373bc4efbfdc3a9256a021d3d5a7c3e26336b19d562516b608353a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Cencora (NYSE:COR) and its peers.",
                "category": "company",
                "datetime": 1788898998,
                "headline": "Q2 Earnings Outperformers: Cencora (NYSE:COR) And The Rest Of The Health Insurance Providers Stocks"
              },
              {
                "id": 141951994,
                "url": "https://finnhub.io/api/news?id=a375fbe02b4405ef0067332de8bf694ce053df54419ec167f9bdcd29649615cb",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "COR",
                "summary": "Cencora, Inc. (COR) Wells Fargo 21st Annual Healthcare Conference September 8, 2026 9:30 AM EDTCompany ParticipantsRobert Mauch - President, CEO &...",
                "category": "company",
                "datetime": 1788870332,
                "headline": "Cencora, Inc. (COR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"
              }
            ],
            "raw_source": [
              {
                "id": 142727641,
                "url": "https://finnhub.io/api/news?id=53319798fa49c05ae6ed79b7b62a4f1103c6e733ae092d29854fdbea50b44a0b",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "COR",
                "summary": "Cencora (NYSE:COR) held its third-quarter earnings conference call on Wednesday. Below is the complete transcript from the call.\nThis transcript is brought to you by Benzinga APIs. For real-time access to our entire",
                "category": "company",
                "datetime": 1791438829,
                "headline": "Cencora Q3 2026 Earnings Call Transcript"
              },
              {
                "id": 142727642,
                "url": "https://finnhub.io/api/news?id=983b64903304cbc8987abdbc4b5b92b8bda18628430e143487e03ffa3d4ce7ac",
                "image": "",
                "source": "Benzinga",
                "related": "COR",
                "summary": "Leerink Partners  analyst Michael Cherny   maintains Cencora (NYSE:COR) with a Outperform and raises the price target from $380 to $388.",
                "category": "company",
                "datetime": 1791377796,
                "headline": "Leerink Partners Maintains Outperform on Cencora, Raises Price Target to $388"
              },
              {
                "id": 142662955,
                "url": "https://finnhub.io/api/news?id=a79264aca14b600f8fd73874c113158161ffe44d0b27110d763f44af3d82f8bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Eli Lilly's revenue surged 44.7% in 2025, but Novo Nordisk trades at less than a quarter of its valuation multiple, a stark contrast that reshapes the risk-reward calculus.",
                "category": "company",
                "datetime": 1791293401,
                "headline": "Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142652817,
                "url": "https://finnhub.io/api/news?id=d11344c10f5ec7aaa66a54cfe75864bb6d79d9cffc1b3aad8016ddc425868a66",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2284502960/image_2284502960.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "COR",
                "summary": "Despite some market underperformance, Cencora's specific business and macro fundamentals remain supportive. Read why COR stock is a Buy.",
                "category": "company",
                "datetime": 1791258499,
                "headline": "Cencora Remains A Buy At These Prices, As Healthcare Supply-Chain Needs Grow"
              },
              {
                "id": 142624185,
                "url": "https://finnhub.io/api/news?id=773d3787e684fba498bba3b49094c209329c0e46fcca5973e7c495eb6d0c1b89",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioritize income stability or growth potential.",
                "category": "company",
                "datetime": 1791124497,
                "headline": "Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142588629,
                "url": "https://finnhub.io/api/news?id=b718d8f4ba73fb930f8c88752552a3630a0e84a6f67c8554d7f840374c8ff04f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "CONSHOHOCKEN, Pa., October 02, 2026--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2026 on Wednesday, November 4, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 4, 2026.",
                "category": "company",
                "datetime": 1790942400,
                "headline": "Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release"
              },
              {
                "id": 142582591,
                "url": "https://finnhub.io/api/news?id=168f9badca7040d68c74b634cf09d64a780542e9820e53c97d9382a9a8b775c0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.",
                "category": "company",
                "datetime": 1790934123,
                "headline": "2 Cash-Producing Stocks with Promising Prospects and 1 We Brush Off"
              },
              {
                "id": 142563714,
                "url": "https://finnhub.io/api/news?id=e98e6cb8cdda4ddef333d043a63b0f58a5549656408252b35331ef9926a27d67",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "AbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly double the profit margin.",
                "category": "company",
                "datetime": 1790894462,
                "headline": "AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142522612,
                "url": "https://finnhub.io/api/news?id=39c8b0d65d016661fc240daa4dc5d5c622c60cf374cedbb1865d36d02d4b09f9",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2233434722/image_2233434722.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "COR",
                "summary": "Cardinal Health remains a Buy, driven by robust FY2026 results, strong cash flow, and credible FY2027 guidance. Read more on CAH stock here.",
                "category": "company",
                "datetime": 1790780492,
                "headline": "Cardinal Health: I'm Still Buying After Checking The Numbers"
              },
              {
                "id": 142519813,
                "url": "https://finnhub.io/api/news?id=17ec7e19223b3ea07ff36979b275faa1c28e02702f7b5ca9bafd798374df9a48",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "COR",
                "summary": "Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session.",
                "category": "company",
                "datetime": 1790778901,
                "headline": "Wednesday's session: gap up and gap down stock in the S&P500 index"
              },
              {
                "id": 142495695,
                "url": "https://finnhub.io/api/news?id=e4914a606e5e89c31d15e5d78f5fe1f1055347a74281b15b6e197065508343dc",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "COR",
                "summary": "Cencora (NYSE:COR) has outperformed the market over the past 5 years by 8.44% on an annualized basis producing an average annual return of 20.45%. Currently, Cencora has a market capitalization of $57.98 billion.",
                "category": "company",
                "datetime": 1790613033,
                "headline": "$100 Invested In Cencora 5 Years Ago Would Be Worth This Much Today"
              },
              {
                "id": 142465609,
                "url": "https://finnhub.io/api/news?id=7d080c740ce7a9ad95d8fdd680bc0d2e0a22695f2ebb3d30dad11f38ee47b7f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.",
                "category": "company",
                "datetime": 1790601516,
                "headline": "1 of Wall Street’s Favorite Stocks with Impressive Fundamentals and 2 We Turn Down"
              },
              {
                "id": 142426107,
                "url": "https://finnhub.io/api/news?id=3c443fa180b195a06f52ced8a8b5d4a24a692b809dd175762819f3d8ae4b1d19",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.",
                "category": "company",
                "datetime": 1790371321,
                "headline": "AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?"
              },
              {
                "id": 142421257,
                "url": "https://finnhub.io/api/news?id=b0d89fe02f5adb02c0ffbd827739d57c3e48106d68fb905d7a05435cf6eaf5c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "CONSHOHOCKEN, Pa., September 25, 2026--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 2026.",
                "category": "company",
                "datetime": 1790337600,
                "headline": "Cencora Elects Robert E. Sanchez to Its Board of Directors"
              },
              {
                "id": 142386749,
                "url": "https://finnhub.io/api/news?id=a527e44c28e4d2901c54177a49412223ada2e94c09864f8c6483e6026a3335f0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Novo Nordisk trades at a steep discount on earnings and sales, while AbbVie grapples with patent cliffs and pricing pressure, but profitability tells a different story.",
                "category": "company",
                "datetime": 1790284741,
                "headline": "AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142386737,
                "url": "https://finnhub.io/api/news?id=8eb972c08a04133027eb920e3fc3b121b93a21bf2259240dd130d95008f10fd5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuations.",
                "category": "company",
                "datetime": 1790281321,
                "headline": "AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142337859,
                "url": "https://finnhub.io/api/news?id=5e90da72b9445f8f269fe769a77eee231cb102829bca91c22fcabee80a02ffe0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "CAH is expanding its MSO strategy across specialty care, with Solaris and broader services aimed at scaling physician networks.",
                "category": "company",
                "datetime": 1790083920,
                "headline": "Can CAH's MSO Expansion Unlock Growth in Specialty Care Delivery?"
              },
              {
                "id": 142315822,
                "url": "https://finnhub.io/api/news?id=3e59c5a142d490e9f2d3d2ec72f8bffda0c3472f6744f8f7756c20aa1a5b6325",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Cencora (NYSE:COR) executives said the company expects its specialty-focused strategy to support continued growth into fiscal 2027, citing demand in oncology and retina, expanded physician-services capabilities and momentum in its international businesses. Speaking at the Morgan Stanley Global Heal",
                "category": "company",
                "datetime": 1790031728,
                "headline": "Cencora Sees Specialty Strategy Fueling Growth Into Fiscal 2027"
              },
              {
                "id": 142308858,
                "url": "https://finnhub.io/api/news?id=3bb5b5a455323b2d2625a5ec535d1f0028338bbb38d12411de24647de5bcea27",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Cencora (NYSE:COR) executives highlighted the company’s specialty pharmaceutical positioning, medical specialty organization strategy and capital-allocation priorities during an investor conference discussion, while reaffirming the durability of its relationship with Walgreens. Chief Executive Offi",
                "category": "company",
                "datetime": 1789984924,
                "headline": "Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at Conference"
              },
              {
                "id": 142289012,
                "url": "https://finnhub.io/api/news?id=a46dc376ff20cc5020fa2758951534772ec27b451a1e7b71bbe3cfb6e7252a2a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Cencora (COR) just combined a stronger fiscal third quarter, a higher full year adjusted EPS outlook, and a US$1b buyback with plans to brief investors at two New York healthcare conferences. Despite the upbeat earnings message, Cencora’s share price has eased in the short term, with a 7 day share price return of down 3.98% and a 30 day share price return of down 2.91% from US$308.78. At the same time, a 90 day share price return of 13.82% and a 1 year total shareholder return of 7.28% sit...",
                "category": "company",
                "datetime": 1789913304,
                "headline": "Cencora (COR) Lifts EPS Outlook And Buyback, Is The Stock Still Below Fair Value?"
              },
              {
                "id": 142271052,
                "url": "https://finnhub.io/api/news?id=43f6da2bdc370d90df2f35e5bc95ec1f7dbb6c62d461277f16c156c2d243919f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "On August 5, Cencora (NYSE:COR) reported results for its fiscal third quarter, which closed on June 30, and the headline numbers looked clean. Revenue rose 5.1% to $84.8 billion, adjusted earnings per share climbed 12.0% to $4.48, and management raised its full-year adjusted EPS outlook to $17.75 to $17.95. The company also repurchased $1 billion […]",
                "category": "company",
                "datetime": 1789821517,
                "headline": "Cencora (COR) Raised Guidance and Bought Back $1B. What’s the Catch?"
              },
              {
                "id": 142209240,
                "url": "https://finnhub.io/api/news?id=55dcd375ad8f39ea5fcbcc3e52e5ac6a03f402dcbb7aa3a622440b2390f1f1c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Cencora Global Chief Data and Information Officer Pawan Verma spoke with WSJ Leadership Institute President Alan Murray at the WSJLI Technology Council Summit about how AI is being used in healthcare to speed access to treatment. Verma described a retinal oncology use case in which doctors analyze large volumes of imaging data to determine treatment, saying Cencora is helping cut a decision process that can take 30 to 90 days roughly in half.",
                "category": "company",
                "datetime": 1789588680,
                "headline": "Cencora Tech Chief: AI Is Cutting Some Medical Treatment Decisions in Half"
              },
              {
                "id": 142168849,
                "url": "https://finnhub.io/api/news?id=b34af31dcda5b814375c7dd7a24aeb1542306abf17d73d352a1296887c2d010c",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "COR",
                "summary": "Cencora, Inc. (COR) 2026 Global Healthcare Conference September 15, 2026 3:10 PM EDTCompany ParticipantsEva Boratto - Executive VP & CFORobert Mauch -...",
                "category": "company",
                "datetime": 1789495297,
                "headline": "Cencora, Inc. (COR) Presents at 2026 Global Healthcare Conference Transcript"
              },
              {
                "id": 142166076,
                "url": "https://finnhub.io/api/news?id=2f736bb4d1187dcfcddd8311592c68845053d1ae300605a4350bbf0f9ff1ab29",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "A panel of CIOs from Indeed, New York Life and Cencora discuss the risks and advantages of enterprise AI, including operational efficiency, financial waste and the need to implement “control towers” for human oversight of consequential decisions.",
                "category": "company",
                "datetime": 1789482540,
                "headline": "The Realities of Managing Enterprise AI"
              },
              {
                "id": 142164126,
                "url": "https://finnhub.io/api/news?id=a66b11ff690d6b717fc56cc954cbd060c681b8a97b4cc86d4699d13e6d045cf8",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "COR",
                "summary": "Cencora, Inc. (COR) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 8:30 AM EDTCompany ParticipantsRobert Mauch - President, CEO...",
                "category": "company",
                "datetime": 1789470099,
                "headline": "Cencora, Inc. (COR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript"
              },
              {
                "id": 142139308,
                "url": "https://finnhub.io/api/news?id=8f218e6f7b910d123201ac23fb800ce70f363d4a3dd35a78f17158dcc3292a09",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a gene-editing breakthrough that could reshape medicine.",
                "category": "company",
                "datetime": 1789398055,
                "headline": "AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142137142,
                "url": "https://finnhub.io/api/news?id=b5abd7161204468ca6b4b5d9aea784815ed678a951caf7db52db72d58e5aff1f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Nate Massari’s business development and commercialization expertise in Immunology & Inflammation (I&I), particularly in ulcerative colitis and Crohn’s disease, will support the advancement of Coultreon's first-in-class SIK3 inhibitor COL-5671 Leuven, Belgium. September 14, 2026. Coultreon Biopharma, a clinical-stage biotechnology company developing best-in-class immunology therapies, today announced the appointment of Nate Massari as Chief Business Officer. Nate brings more than 25 years of expe",
                "category": "company",
                "datetime": 1789390800,
                "headline": "Coultreon Biopharma Appoints Nate Massari as Chief Business Officer"
              },
              {
                "id": 142135993,
                "url": "https://finnhub.io/api/news?id=da1e88d3e7f35b8059dfd20fd97ed62f63419a669479637d7a9f61c48ee2f6bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Amgen trades at a cheaper valuation but carries higher leverage, while Vertex boasts pristine finances and 32% net margins, a classic trade-off between value and quality.",
                "category": "company",
                "datetime": 1789383825,
                "headline": "Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142132277,
                "url": "https://finnhub.io/api/news?id=61290999a6a25626631ed778e2196923d31c2a4fa838d94564f8ae7ff970ab8b",
                "image": "https://www.chartmill.com/images/uploads/thumbnail_article_luc_kroeze_c1f44c837d.webp",
                "source": "ChartMill",
                "related": "COR",
                "summary": "Cencora (COR) scores well on EBIT growth, cash-backed profits and debt/FCF, but thin margins and high debt/equity warrant caution for quality investors.",
                "category": "company",
                "datetime": 1789373469,
                "headline": "Cencora (NYSE:COR): A Quality Stock With Strong EBIT Growth and Cash Conversion"
              },
              {
                "id": 142089518,
                "url": "https://finnhub.io/api/news?id=2b34a2a5a93661fb44b03a5ae23beb9474b495656e1ceef30023166f3e89facb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Cardinal Health's 29% rally reflects stronger specialty growth, MSO expansion and higher-margin assets, but cost pressures could test the uptrend.",
                "category": "company",
                "datetime": 1789150860,
                "headline": "CAH Gains More Than 29% in 4 Months: Will the Uptrend Continue?"
              },
              {
                "id": 142117008,
                "url": "https://finnhub.io/api/news?id=4f3cdc3f142d1235585f184a983f85a7ded779d5b5924bf434d536908a078f6d",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "COR",
                "summary": "Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.79% on an annualized basis producing an average annual return of 20.35%. Currently, Cencora has a market capitalization of $61.36 billion.",
                "category": "company",
                "datetime": 1789149638,
                "headline": "$1000 Invested In Cencora 10 Years Ago Would Be Worth This Much Today"
              },
              {
                "id": 142087142,
                "url": "https://finnhub.io/api/news?id=d6d0c72b86d9e618670b0425256ff71064320995e71838714d702775481e1376",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Amgen is profitable and paying a growing dividend, while Revolution Medicines is burning cash to fund what could be one of the most important cancer drug launches in years.",
                "category": "company",
                "datetime": 1789141777,
                "headline": "Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142087143,
                "url": "https://finnhub.io/api/news?id=76d994f26a70f0f9c15f617bc2f51be0a2aaee74fdcd41e930440fc7f064cf70",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "One company is generating billions in revenue and raising its dividend. The other is burning cash in pursuit of a scientific breakthrough that could change how diseases are treated.",
                "category": "company",
                "datetime": 1789140567,
                "headline": "Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142063302,
                "url": "https://finnhub.io/api/news?id=ad181144a7d06182ba609e0908d03dc6ded85f4ed97764dbd7f7ce1ac0017980",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.",
                "category": "company",
                "datetime": 1789062373,
                "headline": "AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142063433,
                "url": "https://finnhub.io/api/news?id=f57f6954e66790078ae5cddb82a24d663ad81113c4bbf68161a7e0e774309d17",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.",
                "category": "company",
                "datetime": 1789062304,
                "headline": "2 S&P 500 Stocks with Exciting Potential and 1 We Question"
              },
              {
                "id": 142063354,
                "url": "https://finnhub.io/api/news?id=048a492322933b269d7e80caf13a16d0fcc27cc8948d27855f206759fbc84081",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.",
                "category": "company",
                "datetime": 1789057284,
                "headline": "Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142028746,
                "url": "https://finnhub.io/api/news?id=e63b6ec956820a26fe485ffe6e8aea85d06e12f3cc889695166a5af347783058",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Despite lagging behind the Dow over the past 12 months, Cencora continues to receive a highly bullish outlook from Wall Street analysts.",
                "category": "company",
                "datetime": 1788956348,
                "headline": "Is Cencora Stock Underperforming the Dow?"
              },
              {
                "id": 141955203,
                "url": "https://finnhub.io/api/news?id=8eee7a83d373bc4efbfdc3a9256a021d3d5a7c3e26336b19d562516b608353a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Cencora (NYSE:COR) and its peers.",
                "category": "company",
                "datetime": 1788898998,
                "headline": "Q2 Earnings Outperformers: Cencora (NYSE:COR) And The Rest Of The Health Insurance Providers Stocks"
              },
              {
                "id": 141951994,
                "url": "https://finnhub.io/api/news?id=a375fbe02b4405ef0067332de8bf694ce053df54419ec167f9bdcd29649615cb",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "COR",
                "summary": "Cencora, Inc. (COR) Wells Fargo 21st Annual Healthcare Conference September 8, 2026 9:30 AM EDTCompany ParticipantsRobert Mauch - President, CEO &...",
                "category": "company",
                "datetime": 1788870332,
                "headline": "Cencora, Inc. (COR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"
              },
              {
                "id": 141951870,
                "url": "https://finnhub.io/api/news?id=4e7b1a2aeb0c009cfa4b796256f852bfd5d492e932be21782b3689b931c10da5",
                "image": "",
                "source": "Benzinga",
                "related": "COR",
                "summary": "RBC Capital  analyst Ryan Halsted   reiterates Cencora (NYSE:COR) with a Sector Perform and maintains $330 price target.",
                "category": "company",
                "datetime": 1788863860,
                "headline": "RBC Capital Reiterates Sector Perform on Cencora, Maintains $330 Price Target"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 7,
            "negative_hits": 0,
            "positive_hits": 1,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.3,
            "source_article_count": 40,
            "discarded_article_count": 33
          },
          "sentimentPoints": 3
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 19.6,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 2.1,
          "macdPoints": 3.2,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.1,
            "vcp_reason": "波幅收縮(13.6%→8.5%)；站上MA50；升放量(近10日2日)；Ready=N；Confirm=Y",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 1256340,
              "down_days": 4,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 1284700,
              "avg_vol_20": 1265585,
              "avg_vol_30": 1256340,
              "range_pct_10": 0.08526525329810944,
              "range_pct_20": 0.10234939777969816,
              "range_pct_30": 0.135988730792322,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": false,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.0225735071716255,
              "dist_to_20d_high": 0.01997554193277043,
              "down_shrink_days": 2,
              "breakout_level_20d": 327.89999,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.6270023464541634
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 4,
          "volumeWeight": 2,
          "maCrossPoints": 0,
          "shortRsiPoints": 0.4,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.5344016637808724,
              "turnoverUsdM": 287.75125970445004,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.COR",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 305.0614,
            "strength_details": {
              "ma_score": 1,
              "atr_score": 2,
              "rsi_score": 3,
              "macd_score": 2.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.2,
            "stop_loss_percent": 5.1,
            "take_profit_price": 341.2085,
            "target_multiplier": 1.9,
            "technical_strength": 1.93,
            "take_profit_percent": 6.2
          },
          "positionPoints": 1.6,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2231683889345923,
          "stopLossPercent": 5.068803327561745,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 8.1443,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.53
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "適中偏強",
      "score": 8,
      "value": 77.99
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0638
    },
    "kdj": {
      "d": 65.31,
      "j": 111.42,
      "k": 80.68,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 46.4
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": -8523155,
      "recentSlope": 258334.5,
      "previousSlope": -822100
    },
    "rsi": 61.62,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 297.8397,
      "position": "SAR喺價下",
      "distancePct": 7.32,
      "previousTrend": "上升"
    },
    "ma50": 317.9072,
    "macd": {
      "macd": -1.0563306950390938,
      "trend": "看漲",
      "signal": -2.347801540676478,
      "histogram": 1.291470845637384
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 8,
      "value": 311.7308,
      "position": "連續3日>VWAP",
      "consecutiveAbove": 4
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.72,
      "score": 2,
      "avgVolume": 1243042,
      "currentVolume": 895445
    },
    "derived": {
      "ma20": 313.408,
      "ma50": 317.9072,
      "prevClose": 317.25,
      "avgVolume10": 1266105,
      "avgVolume20": 1243042,
      "changePercent": 1.29,
      "avgVolumeForScore": 1243042
    },
    "ma_cross": {
      "ma20": 313.408,
      "ma50": 317.9072,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "熊勢",
      "score": 0,
      "prevMa20": 313.388,
      "prevMa50": 317.8524,
      "spreadPct": 1.42,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 300.1528,
      "upper": 326.6632,
      "position": "上半部"
    },
    "rsi_short": 96.76,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.72
    }
  }
}

{
  "close": 321.35,
  "volume": 895445,
  "changePercent": 1.29
}